Beyondspring Inc
NASDAQ:BYSI
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Sweetgreen Inc
NYSE:SG
|
BM |
|
K
|
Kaulin Manufacturing Co Ltd
TWSE:1531
|
TW |
|
C
|
China Carbon Neutral Development Group Ltd
HKEX:1372
|
HK |
|
G
|
Great Water Holdings Ltd
HKEX:8196
|
CN |
|
B
|
BeiJing Seeyon Internet Software Corp
SSE:688369
|
CN |
|
A
|
Atco Mining Inc
OTC:ATMGF
|
CA |
|
J
|
JSL Industries Ltd
BSE:504080
|
IN |
Beyondspring Inc
Other
Beyondspring Inc
Other Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Beyondspring Inc
NASDAQ:BYSI
|
Other
$19.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
43%
|
CAGR 10-Years
23%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Other
$45m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Other
-$440m
|
CAGR 3-Years
-37%
|
CAGR 5-Years
-26%
|
CAGR 10-Years
20%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Other
-$10.9B
|
CAGR 3-Years
-372%
|
CAGR 5-Years
-161%
|
CAGR 10-Years
-34%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Other
-$366.2m
|
CAGR 3-Years
-30%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Other
-$542.4m
|
CAGR 3-Years
-7%
|
CAGR 5-Years
4%
|
CAGR 10-Years
-5%
|
|
Beyondspring Inc
Glance View
BeyondSpring, Inc. engages in the the development and commercialization of immuno-oncology cancer therapies to improve clinical outcomes for patients who have high unmet medical needs. The company is headquartered in New York City, New York and currently employs 103 full-time employees. The company went IPO on 2017-03-09. The Company’s lead product Plinabulin, which is being studied as an anti-cancer agent in combination with docetaxel in advanced non-small cell lung cancer (NSCLC). The Plinabulin product is a marine-derived small-molecule selective immunomodulating microtubule-binding agent (SIMBA) with a range of immune activities. Its Plinabulin has the immune defense protein, GEF-H1, which leads to two effects: a durable anti-cancer benefits due to the maturation of dendritic cells resulting in activation of tumor antigen-specific T-cells to target cancer cells and early-onset action in chemotherapy-induced neutropenia (CIN) prevention after chemotherapy by boosting the number of hematopoietic stem/progenitor cells (HSPCs).
See Also
What is Beyondspring Inc's Other?
Other
19.9m
USD
Based on the financial report for Dec 31, 2024, Beyondspring Inc's Other amounts to 19.9m USD.
What is Beyondspring Inc's Other growth rate?
Other CAGR 10Y
23%
